A novel pathogenic m.4412G&gt;A <em>MT-TM</em> mitochondrial DNA variant associated with childhood-onset seizures, myopathy and bilateral basal ganglia changes by Lim AZ et al.
Contents lists available at ScienceDirect
Mitochondrion
journal homepage: www.elsevier.com/locate/mito
A novel pathogenic m.4412G>A MT-TM mitochondrial DNA variant
associated with childhood-onset seizures, myopathy and bilateral basal
ganglia changes
Albert Z. Lima, Emma L. Blakelya,b, Karen Batya,b, Langping Hea,b, Sila Hoptona,b,
Gavin Falkousa,b, Kenneth McWilliamc, Alison Cozensd, Robert McFarlanda, Robert W. Taylora,b,⁎
aWellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
bNHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
NE2 4HH, UK
c Department of Paediatric Neurology, Royal Hospital for Sick Children, Edinburgh EH9 1LF, UK
d Inherited Metabolic Disorders Scotland, NHS National Services Scotland, Glasgow G2 6QE, UK
A R T I C L E I N F O
Keywords:
Mitochondrial disease
Myopathy
Seizures
mtDNA variant
Basal ganglia changes
MTTM
A B S T R A C T
Mitochondrial DNA variants in the MT-TM (mt-tRNAMet) gene are rare, typically associated with myopathic
phenotypes. We identified a novel MT-TM variant resulting in prolonged seizures with childhood-onset myo-
pathy, retinopathy, short stature and elevated CSF lactate associated with bilateral basal ganglia changes on
neuroimaging. Muscle biopsy confirmed multiple respiratory chain deficiencies and focal cytochrome c oxidase
(COX) histochemical abnormalities. Next-generation sequencing of the mitochondrial genome revealed a novel
m.4412G>A variant at high heteroplasmy levels in muscle that fulfils all accepted criteria for pathogenicity
including segregation within single muscle fibres, thus broadening the genotypic and phenotypic landscape of
mitochondrial tRNA-related disease.
1. Introduction
The circular mitochondrial DNA (mt-DNA) contains 13 genes that
encode essential subunits of the oxidative phosphorylation complexes,
2 rRNA genes and 22 tRNA genes(Schon et al., 2012). The mitochon-
drial tRNA (mt-tRNA) genes, which contributes< 10% of the total
coding sequence of the mitochondrial genome, are known as patho-
genic hotspots because they are responsible for more than half of
mtDNA-related diseases(Taylor and Turnbull, 2005; Yarham et al.,
2010). The point mutations in them typically cause a loss of its stability
leading to defective mitochondrial translation and combined re-
spiratory chain deficiency(Blakely et al., 2013). Although these mt-
tRNA mutations are responsible for most of the mt-DNA-related dis-
eases in adults phenotypes(Gorman et al., 2015) such as mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)(Goto
et al., 1990) and myoclonic epilepsy with ragged-red fibres (MERRF)
(Shoffner et al., 1990), they are very uncommon in children(Darin
et al., 2001; Scaglia et al., 2004). Furthermore, amongst the mutations
in mt-tRNA genes, those in mt-tRNAMet are rare with clinical cases as-
sociated with just a small number of reported variants (m.4403G>A,
m.4409T>C, m.4440G>A, m.4437C>T and m.4450G>A(Vissing
et al., 1998; Lombes et al., 1998; Olsen et al., 2003; Peverelli et al.,
2014; Scarpelli et al., 2018; Tang et al., 2013; Kuwajima et al., 2019;
Born et al., 2015)). We report a novel m.4412G>A variant in the MT-
TM gene with high levels of heteroplasmy in skeletal muscle in a young
female with disease onset at age 10 years and our work to confirm its
pathogenicity.
2. Materials and methods
2.1. Patient and clinical investigations
Our patient was identified following referral to the UK NHS Highly
Specialised Service for Rare Mitochondrial Disease in Newcastle upon
Tyne, UK. Informed consent from the patient's parents was obtained for
the publication of relevant clinical information including photographs
and all clinical investigations were carried out in accordance to the
Declaration of Helsinki.
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2.2. Histochemical and biochemical analyses
Standard histological (Hematoxylin & Eosin, modified Gomori tri-
chrome staining) and histochemical (cytochrome c oxidase (COX),
succinate dehydrogenase (SDH) and sequential COX-SDH reactions)
analyses were performed on fresh frozen skeletal muscle sections.
Mitochondrial respiratory chain complex activities were evaluated in a
skeletal muscle homogenate and expressed relative to the activity of the
matrix enzyme marker, citrate synthase, as described(Kirby et al.,
2007). Additionally, the mitochondrial oxidative phosphorylation
(OXPHOS) function was assessed using a quadruple im-
munohistochemical assay of Complex I (NDUFB8), complex IV (COX-1)
and porin (mitochondrial mass marker) immunoreactivity as previously
reported(Rocha et al., 2015).
2.3. Molecular genetics
Total DNA was extracted from available tissues (skeletal muscle,
circulating lymphocytes, urinary sediment and buccal epithelial cells)
using standard methodologies. The entire mitochondrial genome was
amplified in two overlapping fragments by long-range PCR of muscle
DNA and analysed by Next Generation sequencing (NGS) using an Ion
Torrent™ Personal Genome Machine (PGM) platform (Thermo Fisher
Scientific). Sequences were aligned to the revised Cambridge sequence
(GenBank Accession number NC_012920.1) for human
mtDNA(Andrews et al., 1999). Almost all of the mitochondrial genome
(99.99%) was covered at a read depth of 200× with a detection sen-
sitivity of ≥5% heteroplasmy for single base substitutions. Data ana-
lysis was performed in Torrent Suite v5.0.4 using Variant Caller
v5.0.4.0 and Coverage Analysis v5.0.4.0.
2.4. Assessment of mutation load by quantitative pyrosequencing
A novel m.4412G>A variant identified following mtDNA sequen-
cing was further assessed by a quantitative pyrosequencing assay using
mutation-specific primers (details available on request). mtDNA het-
eroplasmy levels were determined in DNA samples from the patient and
her mother, as well as individual laser-captured COX-deficient and
COX-positive muscle fibres. Quantification of mtDNA mutation loads
was achieved using Pyromark Q24 software.
3. Results
3.1. Clinical case report
A 10-year-old female Caucasian, born of non-consanguineous par-
ents, had presented with generalised status epilepticus for more than
2 h, thus requiring intubation and admission to a paediatric intensive
Fig. 1. Clinical features. (A) Clinical photography of
the patient (aged 16 years) showing an under-
developed lower jaw. (B) Retinal photography re-
vealed pigmentary changes on her retina. (C) MRI T2
FLAIR coronal view performed at the age of 12 years
showed normal T2 signal in the caudate nucleus. (D)
Similar view performed at the age of 13 years
showed high T2 signal in the caudate nucleus bilat-
erally; the red arrow indicates this abnormality on
the left. This MRI signal change is likely to have
developed during the 1 year interval between the
two scans and coincides with a deterioration in her
gait. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web
version of this article.)
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care unit. Prior to the seizure, she had been well but later recalled that
she had strenuous physical activity at an outdoor pursuit centre. She
was extubated after 24 h and, was discharged home after 3 days without
any apparent neurological sequelae. One year later, at age 11 years, she
had another prolonged generalised tonic-clonic seizure that terminated
with benzodiazepines and intravenous phenytoin.
Apart from recurrent history of prolonged seizures, she had com-
plained of fatigue and reduced exercise tolerance since early childhood.
Her mother recalled that she had difficulties keeping up her peers
around the age 2 years and had tendencies to avoid physical exertion.
For long distances, she required the wheelchair to avoid excessive
tiredness and myalgia. Since the onset of her first seizure, she had
gradually struggled with her gait and felt significantly unsteady around
age 12 years.
Another medical observation was her short stature and poor weight
gain since age 5 years. After an unsuccessful trial of nasogastric tube
feeding, she eventually had percutaneous enteral gastrostomy (PEG) to
improve her growth. Her birth history was unremarkable and her early
neurodevelopment was entirely appropriate, but she had been strug-
gling academically following the onset of her seizures. Both parents
were healthy and her other two siblings were clinically unaffected.
On examination, both her height (1.44 m) and her head cir-
cumference were< 0.4th centile. She was 20 cm shorter than her pre-
dicted mid-parental height of 50th centile (1.64m). Whilst, her weight
had fallen from 75th centile at birth to the current 0.4th-2nd centile at
age 16 years. From the neurological perspective, her gait was broad-
based and her tone was low with proximal weakness. No other sig-
nificant bedside examination findings were observed apart from mild
degree of underdeveloped lower jaw (Fig. 1A) and a PEG tube. Fun-
doscopic examination of her eyes showed evidence of retinitis pig-
mentosa (Fig. 1B).
3.2. Clinical investigations
Her lactate levels were high in both cerebrospinal fluid, (6.9 mmol/
L), and serum, (7.5 mmol/L) as well as mildly elevated creatine kinase
at 316 units/L (normal 25–200 units/L). During her seizure episodes,
her CSF lactate peaked at 17.2mmol/L. All her other clinical laboratory
results including inflammatory markers, kidney function, thyroid
function, neuro-immunology screen, caeruloplasmin, vitamin levels,
free fatty acids, acylcarnithine profile, ammonia, amino acids, urinary
organic acids, autoimmune screen and toxicology screen were normal.
Her initial MRI brain scan at her first seizure presentation age 10 years
and her interim scan at age 12 years showed no significant abnormal-
ities (Fig. 1C) but her subsequent MRI brain imaging at age 13 years
showed high T2 signal in the caudate heads bilaterally (more prominent
on left) (Fig. 1D). In between these brain MRI scans, her gait and co-
ordination deteriorated significantly. Her cardiac review demonstrated
no evidence of cardiomyopathy or conduction abnormalities. The
electroencephalography (EEG) following her prolonged seizure age
10 years showed non-specific encephalopathic changes. Her subsequent
inter-ictal EEG at age 11 years showed normal background activity with
Fig. 2. Histopathological and biochemical evaluation of skeletal muscle. (A) Histological and histochemical analyses of the patient's skeletal muscle biopsy showing
hematoxylin and eosin (H&E) staining (i), cytochrome c oxidase (COX) histochemistry (ii), succinate dehydrogenase (SDH) histochemistry (iii) and sequential COX-
SDH histochemistry (iv), highlighting the marked COX defect; scale bar= 100 μm. (B) The assessment of individual respiratory chain enzyme activities identified a
severe, multiple OXPHOS deficiency affecting complexes I and IV in patient muscle (blue bars) compared to controls (red bars); mean enzyme activities shown for
muscle controls (n=25) are set at 100%. (C) Quadruple immunofluorescence analysis of NDUFB8 (complex I) and COXI (complex IV) mitochondrial subunits,
confirming a multiple OXPHOS defect. Each dot represents the measurement from an individual muscle fibre, colour co-ordinated according to its mitochondrial mass
(low=blue, normal= beige, high=orange, very high= red). Gray dashed lines represent SD limits for classification of the fibres. Lines next to x- and y-axes
represent the levels of NDUFB8 and COXI: beige=normal (> − 3), light beige= intermediate positive (−3 to−4.5), light purple= intermediate negative (−4.5
to −6), purple= deficient (<−6). Bold dashed lines represent the mean expression level of normal fibres. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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a photoparoxysmal response at 22 Hz. There was frontal epileptiform
activity during drowsiness, without clinical concomitant.
3.3. Histochemical and biochemical analyses
Muscle biopsy analysis showed normal fibre size following H&E
staining, with evidence of fat deposition between fibres and fascicles
(Fig. 2A). In addition, we noted remarkable mitochondrial histochem-
ical abnormalities characterized by a mosaic pattern of COX-deficiency
affecting>80% of all fibres on both the individual enzyme reaction
and the sequential COX-SDH reaction and subsarcolemmal mitochon-
drial accumulation (ragged-blue fibres affecting ~5% of the total
biopsy) on the individual SDH reaction, consistent with a mitochondrial
aetiology (Fig. 2A). The assessment of mitochondrial respiratory chain
enzyme activities in a frozen skeletal muscle homogenate revealed
evidence of severe, multiple respiratory chain defects involving com-
plexes I and IV with sparing of complex II activity, suggestive of a
generalised defect of mitochondrial translation (Fig. 2B). In agreement
with this, quadruple OXPHOS immunofluorescence confirmed the
presence of many muscle fibres lacking both complex I (NDUFB8) and
complex IV (COX-1) expression, confirming a multiple respiratory chain
defect (Fig. 2C).
3.4. Molecular genetic analyses
A peripheral blood leucocyte sample was screened for common
pathogenic mtDNA variants but no abnormalities were detected.
Sequencing of the complete mitochondrial genome revealed a novel
m.4412G>A MT-TM variant at high levels of heteroplasmy (92%
mutation load based on NGS reads) in skeletal muscle. Quantitative
pyrosequencing confirmed high levels of heteroplasmy in skeletal
muscle (90% mutation load), with much lower levels of heteroplasmy
in buccal and urine (6% and 7% respectively) DNA samples. DNA
samples obtained from the patient's mother showed no evidence of the
novel m.4412G>A variant in buccal epithelia, urinary sediment or a
blood sample implying the variant had likely arisen de novo during
embryogenesis and not been maternally-inherited (Fig. 3A). Single
muscle fibre analysis of individual COX-positive and COX-deficient fi-
bres revealed a statistically-significant higher mutation load in COX-
deficient fibres (92.89 ± 0.36% (n=19 fibres)) than in COX-positive
fibres (COX-positive fibres: 70.13 ± 7.12% (n=16 fibres);
p < .0001) confirming pathogenicity of the m.4412G>A variant
(Fig. 3B).
4. Discussion
We described a young female who carried a novel variant,
m.4412A>G in the MT-TM gene, resulting in the childhood onset of
mitochondrial disease with multi-system involvement that included
prolonged seizures, hypotonia, fatigue, proximal muscle weakness, re-
tinopathy and short stature secondary to growth failure. Gross motor
dysfunction was gradually progressive with significant deterioration of
her gait and coordination, which appear to coincide with the devel-
opment of bilateral signal change in the head of caudate on cranial MRI
at age 13 years. Although she had some degree of learning difficulties
following her first seizure, bilateral basal ganglia changes and elevated
Fig. 3. Mitochondrial DNA studies revealing a pathogenic m.4412A>G variant. (A) Family pedigree identifying the level of the novelMT-TM variant in the proband
(indicated by an arrow), and the absence of this variant in all tissues tested in her mother. (B) Single fibre PCR analysis clearly shows a marked segregation of the
m.4412A>G mutation with a biochemical defect in individual COX-deficient muscle fibres which harbour higher levels of mutation than COX-positive fibres (see
text for details); each symbol represents data for one fibre. (C) Phylogenetic conservation of this region of theMT-TM gene sequence indicates the mutation affects an
evolutionary conserved residue and base pair within the DHU stem, as further illustrated on the schematic representation of the mt-RNAMet cloverleaf structure (D).
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CSF lactate levels, this girl did not have the typical stepwise neuro-
regression to fulfil the criteria for a diagnosis of Leigh syndrome, the
commonest syndromic presentation of paediatric mitochondrial dis-
ease.
We believe that the novel m.4412A>G MT-TM gene variant can be
classed as pathogenic for several reasons. First, this variant was not
listed on a publically-accessible mitochondrial genome database
(http://www.mitomap.org/) which contains Genbank frequency data
from 47,412 human mitochondrial DNA sequence or our own in-house
database of> 1900 mtDNA sequences. Second, the highest level of
mutation was found in clinically-affected skeletal muscle, with lower
levels in blood. Third, this mutation appeared to have arisen de novo
and was not detected in the patient's asymptomatic mother.
Furthermore, this variant was located within the D-stem of the mt-
tRNAMet molecule disrupting an evolutionary-conserved Watson-Crick
base pair within this stem which alters tRNA secondary structure and
impedes its function (Fig. 3C and D). In addition, we demonstrated
histochemical evidence of marked Complex I and Complex IV defi-
ciency in muscle as evidence of a generalised defect of translation,
consistent with a mt-tRNA defect. The most important evidence of pa-
thogenicity is the single fibre segregation study which established that
this variant segregates with the COX histochemical defect in her ske-
letal muscle tissue, thus confirming its pathogenicity. Using the vali-
dated scoring system(Yarham et al., 2011) which encompasses the
biochemical and molecular genetics to assign pathogenicity, this
m.4412A>G base substitutions had also reached the required
threshold (a score of 13 out of 20) to distinguish itself from poly-
morphic changes in the mt-tRNA.
Our affected child has the earliest disease onset compared to the
other reported cases of m.4409T>C, m.4403T>C, m.4440G>A,
m.4437C>T and m.4450G>A variants within the MT-TM gene; the
clinical phenotypes of these reported cases are summarised in Table 1.
Most of these patients including ours, had progressive myopathy with
elevated creatine kinase(Vissing et al., 1998; Peverelli et al., 2014;
Scarpelli et al., 2018; Born et al., 2015). Interestingly, our young pa-
tient also had the highest heteroplasmy level in the muscle, suggesting
that this extremely high mutation load might have predisposed her to
an earlier onset of disease than the other reported patients who only
became symptomatic later. Apart from the muscle phenotype, epileptic
seizure have also been reported associated with the m.4437C>T and
m.4450G>A variants(Tang et al., 2013; Kuwajima et al., 2019). One
patient with m.4450G>A presented with a” stroke-like” episode,
along with unilateral occipital lobe and bilateral basal ganglia changes
(Kuwajima et al., 2019). Short stature, as documented in our patient,
was observed in another patient(Vissing et al., 1998). As far as we
know, none of the reported patients with pathogenic MT-TM variants
had status epilepticus and pigmentary retinopathy as described in our
patient. This paediatric case expands the current phenotypic spectrum
of disease related to MT-TM mutations, as well as our understanding of
pathogenic mt-tRNA gene variants and their impact across both pae-
diatric and adult specialities.
5. Conclusion
In summary, we report a novel m.4412A>G variant in the MT-TM
gene presenting with childhood-onset mitochondrial disease char-
acterized by myopathy, prolonged seizures, retinopathy, short stature,
lactic acidosis and bilateral basal ganglia changes. This mtDNA novel
variant adds to the list of pathogenic MT-TM variants and illustrates the
importance of a diagnostic muscle biopsy in demonstrating histocyto-
chemical mitochondrial abnormalities and supporting single-fibre seg-
regation studies.
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